Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Dizal’s JAK1 Inhibitor NDA Accepted for China Review as PTCL Therapy

publication date: Sep 15, 2023

Shanghai Dizal Pharma reported its NDA for golidocitinib was accepted by China’s CDE for review as a treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor that showed efficacy in a global, multicenter pivotal study. In a trial that enrolled 112 r/r PTCL patients, golidocitinib produced an ORR of 44% and a CRR of 24%. One month ago, Dizal announced that its lead drug, sunvozertinib, was approved for China use as a second line therapy for NSCLC with EGFR exon 20 insertion mutations. More details.... 

Stock Symbol: (SHA: 688192)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital